135 results about "L-Isoleucine" patented technology

PCT No. PCT / JP96 / 02503 Sec. 371 Date Mar. 2, 1998 Sec. 102(e) Date Mar. 2, 1998 PCT Filed Sep. 4, 1996 PCT Pub. No. WO97 / 08946 PCT Pub. Date Mar. 13, 1997The present invention aims to provide a medium composition for in vitro fertilization, in particular, a composition usable in the culture of ova or early embryos which are fertilized eggs, the preparation or culture of sperm, and the pre-treatment of ova or sperm. The composition comprises, as its essential components, L-phenylalanine, L-tryptophan, L-lysine, L-threonine, L-valine, L-methionine, L-isoleucine, L-leucine, L-proline, glycine, L-alanine, L-tyrosine, L-histidine, L-arginine, L-taurine, L-aspartic acid, L-serine, L-asparagine, L-glutamic acid, L-glutamine and L-cystine, provided that at least a part of the L-cystine may be replaced by L-cysteine.

Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing lyophilization using a mixture comprising 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits an unstable activity during lyophilization, rather than using human blood derived albumin.

A method of treating a patient for a condition characterized by symptoms that can be alleviated by interfering with or supplementing the activity of endogenous ligands on the a2S subunit of a voltage gated calcium channel, said method comprising: administering to a patient experiencing the condition an amount of one or more of L-norleucine, L-isoleucine, L-alloisoleucine, L-methionine, Lleucine, 2-cyclohexylglycine, 2-phenylglycine, 2-amino-2-norbornane carboxylic acid, 1-aminocyclohexane carboxylic acid, 2-aminoheptanoic acid, 2-aminocaprylic acid, and 2-aminononanoic acid under conditions effective to treat the condition, wherein when the condition is a hot flash or a symptom of hormonal variation, the compound is not L-leucine.

The invention belongs to the technical field of pharmaceutical chemistry, and discloses a preparation method of semaglutide and an intermediate of semaglutide. The preparation method comprises: obtaining a compound having a structure represented as the formula I by taking a resin, activating the resin, and coupling L-glycine, L-arginine, L-glycine, L-arginine, L-valine, L- leucine, L-tryptophan, L-alanine, L-isoleucine, L-phenylalanine, and L-glutamic acid to the activated resin step by step so as to obtain a first peptide resin; taking the first peptide resin, and coupling amino acids or amino acid derivatives to the second peptide resin step by step; and taking the second peptide resin, and performing cracking and purifying to obtain semaglutide. According to the method, the compound having a structure represented as the formula I is taken as an intermediate and coupling of each amino acid or amino acid derivative step by step through solid-phase synthesis is carried out, thereby improving the yield of semaglutide. In the formula I, R1 is selected from Fmoc, Boc, and ivDde, and R2 is selected from tBu, Dmab, and Bzl.

Amino acid compositions which contain 10 to 40 parts by weight of L-arginine, 10 to 40 parts by weight of L-glutamine, 5 to 20 parts by weight of L-valine, 8 to 30 parts by weight of L-isoleucine, and 10 to 35 parts by weight of L-leucine may be taken orally and are effective for reducing body fat without dietary restrictions and exercise.

The invention discloses a medicine combination which contains 15 amino acids and the preparation method thereof; the medicine combination is characterized in that a compound amino acid injecta with different concentrations are prepared by the 15 amino acids which serve as raw materials and admixture according to the following parts by weight: 6.1-10.8 parts of L-Isoleucine, 8.8-16.6 parts of L-Leucine, 4.6-10.4 parts of L-Lysine Acetate, 0.8-3.0 parts of L-Methionine, 0.8-3.9 parts of L-Phenylalanine, 1.6-5.4 parts of L-threonine, 0.5-1.1 parts of L-Tryptophan, 6.7-10.7 parts of L-Valine, 3.2-9.3 parts of L-alanine, 4.6-7.2 parts of L-arginine, 1.2-2.9 parts of L-Histidine, 5.0-9.6 parts of L-proline, 2.6-6.0 parts of L-serine, 2.6-10.8 parts of glycin, 0.1-1.0 parts of L-Cysteine hydrochloride, 0.1-0.5 parts of citric acid and moderate water for injection. The injecta does not contain sulphite type chemical inhibitor, thoroughly solves the harm of sulphite type on human body, and ensures that the obtained products are safer. The PH value of the injecta is 5.5-7.0. By the accelerated test and quality test, the results show that the stability of the medicine combination which contains 15 amino acids is the same as or better than like products which contains sulphite type sold on market.

The invention discloses a method for extracting L-isoleucine, belonging to the field of biochemical engineering. The method disclosed by the invention comprises the following steps of: flocculating an L-isoleucine fermentation liquid, and micro-filtering the flocculated clear solution by using a ceramic membrane with pore diameter of 50nm and molecular weight of 30KD; adsorbing the filtration liquid obtained by micro-filtration by using strong acid cation exchange resin, eluting the strong acid cation exchange resin by using 0.2-0.6mol / L ammonia water or sodium hydroxide, collecting an elution liquid A from the starting of elution to the moment when the pH value of the elution liquid is 7-8, and collecting an elution liquid B from the moment when the pH value of the elution liquid is 7-8 to the moment when the pH value of the elution liquid is 9.5-10.5; concentrating, filtering and decolorizing the elution liquid A, crystallizing to obtain L-isoleucine crystals, and repeating ion exchange adsorption on the elution liquid B. The method can be used for effectively removing impurities in the filtration liquid and the elution liquids, increases the extraction rate and the quality of L-isoleucine and can be widely applied to the production of the L-isoleucine.

The normal temperature and sub-normal temperature in vitro heart preserving perfusate as one kind of organ preserving matter consists of basic electrolyte, energy matter and protecting matter. Each liter of the heart preserving perfusate contains NaCl 5.0-7.0 g, KCl 0.3-0.5 g, NaH2PO4 .H2O 100-150 mg, MgSO4 50-100 mg, NaHCO3 3.0-5.0 g, L-argine 70-100 mg, histidine 30-60 mg, L-cystine 50-70 mg, L-methionine 10-50 mg, levo glutamine 500-700 mg, L-lysine 100-170 mg, glycine 10-50 mg, L-isoleucine 70-150 mg, L-serine 30-50 mg, L-leucine 70-150 mg, L-tryptophane 10-20 mg, L-tyramine 80-150 mg, L-valine 70-150 mg, L-threonine 80-150 mg, choline chloride 3-8 mg, vitamin B2 0.5-3 mg, pantothenic acid 3-g mg, folic acid 3-8 mg, pyridoxal 3-10 mg, nicotinamide 3-10 mg, etc. The present invention has the effects of preserving in vitro heart efficiency, reducing rejection reaction of organ and prolonging the survival period of organ.

The present invention provides one kind of functional sports drink and aims at providing one kind of functional sports drink capable of regulating body fluid balance, delaying fatigue and promoting restoring from fatigue. The drink contains sweetener, citric acid, L-arginine, L-leucine, L-isoleucine, L-valine, Na, K, Ca, Mg, edible essence and pure water. The preparation process includes dissolving all the functional components in pure water via heating, filtering, mixing, superhigh temperature instantaneous sterilizing, packing and cooling.

An embodiment of the present invention relates to a salty taste enhancer containing an amino acid and / or a derivative thereof, the amino acid being L-leucine, or L-leucine and L-isoleucine. At least one embodiment provides: (i) a salty taste enhancer which is capable of effectively enhancing a salty taste of food or drink, (ii) food or drink containing the salty taste enhancer, and / or (iii) a method for producing the food or drink.